

RESULTS OF THE ANNUAL GENERAL MEETING

Melbourne, Australia, 27 November 2020: BARD1 Life Sciences Limited (ASX:BD1) (**BARD1** or **Company**) announces the results of the Annual General Meeting that concluded after the market closed on 26 November 2020.

All resolutions were carried except for resolution 4 which was withdrawn before the meeting.

In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, we advise details of the resolutions and the proxies received in respect of each resolution are set out in the attached proxy summary.

Tony Di Pietro
Company Secretary

- ENDS -

COMPANY CONTACTS

Dr Leearne Hinch
CEO
E leearne@bard1.com
M +61 400 414 416

Dr Geoff Cumming
Non-executive Chairman
E geoff.cumming@bard1.com
M +61 417 203 021

ABOUT BARD1 LIFE SCIENCES LTD

BARD1 Life Sciences Ltd (ASX:BD1) (**BARD1** or the **Company**) is a leading Australian diagnostics company with an innovative portfolio of diagnostic technologies and products. The Company is focused on developing and commercialising best-in-class diagnostic solutions for healthcare professionals and patients. The cancer diagnostics portfolio includes the commercialised hTERT test used as an adjunct to urine cytology testing and diagnostic tests in development for ovarian, breast, lung, prostate and pancreatic cancers. For more information on BARD1, see www.bard1.com.

FORWARD LOOKING STATEMENTS

This announcement contains certain 'forward-looking statements' within the meaning of the securities laws of applicable jurisdictions. Forward-looking statements can generally be identified by the use of forward-looking words such as 'may,' 'should,' 'expect,' 'anticipate,' 'estimate,' 'scheduled' or 'continue' or the negative version of them or comparable terminology. Any forecasts or other forward-looking statements contained in this announcement are subject to known and unknown risks and uncertainties and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct. There are usually differences between forecast and actual results because events and actual circumstances frequently do not occur as forecast and these differences may be material. The Company does not give any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements in this announcement will actually occur and you are cautioned not to place undue reliance on forward-looking statements.

BARD1 LIFE SCIENCES LIMITED
ANNUAL GENERAL MEETING
Thursday, 26 November 2020
Results of Meeting

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried
1 Adoption of Remuneration Report	Ordinary	854,385,839 92.33%	51,230,586 5.53%	19,879,300 2.14%	13,668,842	881,606,709 94.10%	55,230,586 5.90%	13,668,842	Carried
2 Election of Professor Allan Cripps as Director	Ordinary	988,657,111 95.28%	29,077,929 2.80%	19,939,300 1.92%	42,920,001	1,017,937,981 97.22%	29,077,929 2.78%	44,920,001	Carried
3 Election of Dr Geoffrey Cumming as Director	Ordinary	988,281,963 95.24%	29,452,362 2.84%	19,939,300 1.92%	42,920,716	1,017,221,263 97.15%	29,793,932 2.85%	44,920,716	Carried
4 Election of Helen Fisher as Director	Ordinary	WITHDRAWN				WITHDRAWN			
5 Approval of 10% Placement Capacity	Special	1,023,503,497 96.67%	15,300,920 1.45%	19,939,300 1.88%	21,850,624	1,032,942,797 96.71%	35,142,490 3.29%	23,850,624	Carried
6 Share Consolidation	Ordinary	964,426,325 90.33%	83,284,602 7.80%	19,939,300 1.87%	12,944,114	993,365,625 92.24%	83,626,172 7.76%	14,944,114	Carried

* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.